| |
GC |
MG |
| Patients (No) |
83 |
89 |
| Age |
|
|
| Mean |
61.1 |
69.3 |
| SD (s) |
11.8 |
15.4 |
| Median |
62 |
71 |
| Range |
(30-86) |
(24-97) |
| Primary Tumor site |
|
|
| Nasopharynx |
9 (11%) |
12(13%) |
| Oral cavity |
26(31%) |
21(24%) |
| Salivary glands |
2(2%) |
2(2%) |
| Oropharynx |
9 (11%) |
9 (10%) |
| Nasal cavity and paranasal sinuses |
4(5%) |
5(6%) |
| Hypopharynx |
1(1%) |
1(1%) |
| Larynx |
19(23%) |
28(32%) |
| Thyroid |
5(6%) |
1(1%) |
| Ear |
5(6%) |
3(3%) |
| Cervical esophagus |
0(0%) |
5(6%) |
| Unknown primary tumour (UPT) |
3(4%) |
2(2%) |
| Hystologic type |
|
|
| Squamous Carcinoma |
43(52%) |
37(42%) |
| Epidermoid Carcinoma |
29(35%) |
22(25%) |
| Adenocarcinoma |
3(4%) |
5(5%) |
| Mucoepidermoid Carcinoma |
2(2%) |
0 |
| Spinocellular Carcinoma |
1(1%) |
3(3%) |
| Hodgkin lymphoma |
0
0
0 |
2(2%) |
| NHL |
3(3%) |
| Melanoma |
2(2%) |
| Ca papillary |
3(4%) |
2(2%) |
| Ca follicular |
2(2%) |
0 |
| Undifferentiated carcinoma |
0 |
13(15%) |
| Chemotherapy |
|
|
| No |
27(33%) |
62(70%) |
| pre-RT |
28(34%) |
14(16%) |
| concomitant |
19(23%) |
2(2%) |
| pre-RT+concomitant |
9 (11%) |
11(12%) |
| Radiotherapy |
|
|
| T (only) |
9 (11%) |
35(39%) |
| T + N |
64(77%) |
47(53%) |
| N (only) |
10(12%) |
8(9%) |
|